Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2025, titled "Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in three single-dose vial sizes — 750 mg, 1.25 g, and 1.5 g. The product is a generic, bioequivalent and therapeutically equivalent version of Mylan Laboratories' reference listed drug (NDA 209481). According to IQVIA sales data for the 12 months ending January 2025, the US market for these single-dose vials is worth approximately $39.3 million annually. Glenmark management said the launch adds another product to its North American institutional portfolio.
Modestly positive for shareholders — adds a new revenue stream from the US generics market in hard currency, though the addressable market size of ~$39.3 million limits the immediate financial impact. Strengthens Glenmark's growing institutional injectables portfolio in North America.